Suppr超能文献

雷特综合征照顾者症状严重程度评估(RCASS)的心理测量评估

Psychometric Assessment of the Rett Syndrome Caregiver Assessment of Symptom Severity (RCASS).

作者信息

Raspa Melissa, Gwaltney Angela, Bann Carla, von Hehn Jana, Benke Timothy A, Marsh Eric D, Peters Sarika U, Ananth Amitha, Percy Alan K, Neul Jeffrey L

机构信息

RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC, 27708, USA.

Rett Syndrome Research Trust, Trumbull, USA.

出版信息

J Autism Dev Disord. 2025 Mar;55(3):997-1009. doi: 10.1007/s10803-024-06238-0. Epub 2024 Mar 5.

Abstract

Rett syndrome is a severe neurodevelopmental disorder that affects about 1 in 10,000 females. Clinical trials of disease modifying therapies are on the rise, but there are few psychometrically sound caregiver-reported outcome measures available to assess treatment benefit. We report on a new caregiver-reported outcome measure, the Rett Caregiver Assessment of Symptom Severity (RCASS). Using data from the Rett Natural History Study (n = 649), we examined the factor structure, using both exploratory and confirmatory factor analysis, and the reliability and validity of the RCASS. The four-factor model had the best overall fit, which covered movement, communication, behavior, and Rett-specific symptoms. The RCASS had moderate internal consistency. Strong face validity was found with age and mutation type, and convergent validity was established with other similar measures, including the Revised Motor-Behavior Assessment Scale, Clinical Severity Scale, Clinical Global Impression Scale, and the Child Health Questionnaire. These data provide initial evidence that the RCASS is a viable caregiver-outcome measure for use in clinical trials in Rett syndrome. Future work to assess sensitivity to change and other measures of reliability, such as test-retest and inter-rater agreement, are needed.

摘要

瑞特综合征是一种严重的神经发育障碍,每10000名女性中约有1人受其影响。改善病情疗法的临床试验正在增加,但可用于评估治疗效果的、在心理测量方面合理的照料者报告结局指标却很少。我们报告了一种新的照料者报告结局指标,即瑞特综合征照料者症状严重程度评估(RCASS)。利用瑞特综合征自然史研究的数据(n = 649),我们通过探索性和验证性因素分析研究了RCASS的因素结构及其信度和效度。四因素模型总体拟合最佳,涵盖运动、沟通、行为和瑞特综合征特异性症状。RCASS具有中等程度的内部一致性。在年龄和突变类型方面发现了较强的表面效度,并与其他类似指标建立了收敛效度,这些指标包括修订版运动行为评估量表、临床严重程度量表、临床总体印象量表和儿童健康问卷。这些数据提供了初步证据,表明RCASS是一种可用于瑞特综合征临床试验的可行的照料者结局指标。未来需要开展工作来评估其对变化的敏感性以及其他信度指标,如重测信度和评分者间一致性。

相似文献

1
Psychometric Assessment of the Rett Syndrome Caregiver Assessment of Symptom Severity (RCASS).
J Autism Dev Disord. 2025 Mar;55(3):997-1009. doi: 10.1007/s10803-024-06238-0. Epub 2024 Mar 5.
2
A New Scale to Evaluate Motor Function in Rett Syndrome: Validation and Psychometric Properties.
Pediatr Neurol. 2019 Nov;100:80-86. doi: 10.1016/j.pediatrneurol.2019.03.005. Epub 2019 Mar 16.
3
A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials.
Am J Intellect Dev Disabil. 2020 Nov 1;125(6):493-509. doi: 10.1352/1944-7558-125.6.493.
7
Assessment of a Clinical Trial Metric for Rett Syndrome: Critical Analysis of the Rett Syndrome Behavioural Questionnaire.
Pediatr Neurol. 2020 Jun;107:48-56. doi: 10.1016/j.pediatrneurol.2020.01.009. Epub 2020 Feb 4.
8
Validation of the Observer-Reported Communication Ability (ORCA) measure for individuals with Rett syndrome.
Eur J Paediatr Neurol. 2023 Sep;46:74-81. doi: 10.1016/j.ejpn.2023.07.007. Epub 2023 Jul 28.
9
Assessment of Caregiver Inventory for Rett Syndrome.
J Autism Dev Disord. 2017 Apr;47(4):1102-1112. doi: 10.1007/s10803-017-3034-3.

引用本文的文献

1
Loss of MeCP2 leads to sleep deficits that are time-of-day dependent and worsen with sleep deprivation.
Neurobiol Sleep Circadian Rhythms. 2025 Jun 11;19:100132. doi: 10.1016/j.nbscr.2025.100132. eCollection 2025 Nov.
4
Rett Syndrome: The Emerging Landscape of Treatment Strategies.
CNS Drugs. 2024 Nov;38(11):851-867. doi: 10.1007/s40263-024-01106-y. Epub 2024 Sep 9.
6
Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials.
Brain Sci. 2024 Jan 24;14(2):120. doi: 10.3390/brainsci14020120.

本文引用的文献

1
Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study.
J Neurodev Disord. 2023 Oct 13;15(1):33. doi: 10.1186/s11689-023-09502-z.
2
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.
Nat Med. 2023 Jun;29(6):1468-1475. doi: 10.1038/s41591-023-02398-1. Epub 2023 Jun 8.
4
State-of-the-art therapies for Rett syndrome.
Dev Med Child Neurol. 2023 Feb;65(2):162-170. doi: 10.1111/dmcn.15383. Epub 2022 Sep 3.
5
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.
Epilepsia. 2022 Jul;63(7):1736-1747. doi: 10.1111/epi.17247. Epub 2022 Apr 20.
6
Improving clinical trial readiness to accelerate development of new therapeutics for Rett syndrome.
Orphanet J Rare Dis. 2022 Mar 4;17(1):108. doi: 10.1186/s13023-022-02240-w.
7
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.
Contemp Clin Trials. 2022 Mar;114:106704. doi: 10.1016/j.cct.2022.106704. Epub 2022 Feb 8.
8
The attitude of patients with progressive ataxias towards clinical trials.
Orphanet J Rare Dis. 2022 Jan 4;17(1):1. doi: 10.1186/s13023-021-02091-x.
9
The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment.
Patient. 2021 Sep;14(5):485-503. doi: 10.1007/s40271-020-00493-w. Epub 2021 Jan 19.
10
A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials.
Am J Intellect Dev Disabil. 2020 Nov 1;125(6):493-509. doi: 10.1352/1944-7558-125.6.493.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验